Tada,

Yes, the waters are murkier than Resverlogix indicated back in September to November. I am fully aware of the possible explanations for the delay in events. However, it was a bold statement to state that with 55 days left in the year, a trial running for 3 years would be ending dosing by end of year. Whiff! They communicated clear waters when clearly that was far from true. They also have 12 days left to achieve their other projection of MACE occuring at 10-15 per month. 200 events on September 12 plus 10 per month puts them at 250 by February 12.

As for your other comment about the SSRA, "(SSRA) Don clearly stated at the Sept 2018 AGM that they decided not to do a SSRA as by the time the results would be available we would likely be done the BETonMACE trial. This clear communication seems to be missed by you. This change in path has saved the company a lot of money that would otherwise have created more dilution for all shareholders."

At the AGM they were at 200 events. We are now nearly 5 months past the AGM. It is extremely unlikely that it would take 5 months to complete an interim analysis like the  SSRA. Their explanation at the AGM in September 2018  for skipping the SSRA no longer holds water. Of course, too late NOW five months later since new enrollment would require new patients to be dosed for six months minimum. 

BearDownAZ